Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000
Debt
Debt-to-Equity Ratio-132.64
Current Ratio1.07
Quick Ratio0.91
Price-To-Earnings
Trailing P/E Ratio4.57
Forward P/E Ratio6.74
P/E Growth1.69
Sales & Book Value
Annual Sales$3.47 billion
Price / Sales1.13
Cash Flow$8.3476 per share
Price / Cash2.10
Book Value$2.17 per share
Price / Book8.08
Profitability
EPS (Most Recent Fiscal Year)$3.84
Net Income$-2,035,430,000.00
Net Margins-34.72%
Return on Equity237.45%
Return on Assets6.19%
Miscellaneous
Employees3,039
Outstanding Shares223,930,000
Market Cap$3.93 billion
Endo International (NASDAQ:ENDP) Frequently Asked Questions
What is Endo International's stock symbol?
Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How were Endo International's earnings last quarter?
Endo International PLC (NASDAQ:ENDP) issued its quarterly earnings results on Wednesday, August, 8th. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.54 by $0.22. The firm earned $714.70 million during the quarter, compared to analyst estimates of $679.72 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. Endo International's revenue for the quarter was down 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.93 earnings per share. View Endo International's Earnings History.
When is Endo International's next earnings date?
How can I listen to Endo International's earnings call?
Endo International will be holding an earnings conference call on Thursday, November 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8664970462.
What guidance has Endo International issued on next quarter's earnings?
Endo International updated its FY18 earnings guidance on Wednesday, August, 8th. The company provided earnings per share (EPS) guidance of $2.50-2.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.41. The company issued revenue guidance of $2.75-2.85 billion, compared to the consensus revenue estimate of $2.76 billion.
What price target have analysts set for ENDP?
18 analysts have issued 1 year price targets for Endo International's stock. Their forecasts range from $7.00 to $26.00. On average, they anticipate Endo International's stock price to reach $15.10 in the next twelve months. This suggests that the stock has a possible downside of 13.9%. View Analyst Price Targets for Endo International.
What is the consensus analysts' recommendation for Endo International?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 14 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.
What are Wall Street analysts saying about Endo International stock?
Here are some recent quotes from research analysts about Endo International stock:
- 1. According to Zacks Investment Research, "Endo is in the process of redefining its business, given the persistent decline in the generic business and withdrawal of opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The focus now is on sterile injectables and Xiaflex. Sales of Xiaflex are being driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Revenues from the sterile injectables business are being driven by the continued growth of Adrenalin. The business is poised to become Endo's core business. While the turnaround might take time, the company seems to be on the right track. Shares have outperformed the industry in the year so far. However, the generic business is expected to face further challenges. Competition is expected to intensify further in 2018." (9/24/2018)
- 2. Canaccord Genuity analysts commented, "We view Athenex’s compounded vasopressin launch today as more headline risk than an actual financial hit to Endo’s near-term results. We expect Endo to restart litigation with FDA regarding compounding guidance and we’d also expect patent litigation against Athenex that could potentially enjoin sales of the compounded product. While ENDP shares have had strong momentum of late, we remain concerned that little events like these – along with broader opioid and product litigation – could dent that momentum. As such, we maintain our HOLD rating on ENDP shares." (8/13/2018)
- 3. Cantor Fitzgerald analysts commented, ". We are raising our 12 month PT for ENDP shares to $12 from $7. The increase in our PT is driven by multiple expansion (from 8x to 9x 2019 EV/EBITDA versus 10x for the comps). We think this is deserved since generic drug pricing has stabilized for ENDP, according to the company, and we are optimistic that ENDP could report positive data for CCH to treat cellulite as early as the end of this year versus its official guidance of 2019. The following points support our view." (7/23/2018)
- 4. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)
Are investors shorting Endo International?
Endo International saw a increase in short interest during the month of September. As of September 28th, there was short interest totalling 33,858,926 shares, an increase of 6.2% from the September 14th total of 36,096,754 shares. Based on an average daily trading volume, of 2,925,782 shares, the short-interest ratio is presently 11.6 days. Approximately 16.9% of the company's stock are short sold. View Endo International's Current Options Chain.
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Valeant Pharmaceuticals (VRX), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS) and Catalent (CTLT).
Who are Endo International's key executives?
Endo International's management team includes the folowing people:
- Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)
- Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
- Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
- Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
- Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 61)
Who are Endo International's major shareholders?
Endo International's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.01%) and First Hawaiian Bank (0.01%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International.
Which major investors are buying Endo International stock?
ENDP stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and First Hawaiian Bank. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.
How do I buy shares of Endo International?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endo International's stock price today?
One share of ENDP stock can currently be purchased for approximately $17.53.
How big of a company is Endo International?
Endo International has a market capitalization of $3.93 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.
What is Endo International's official website?
How can I contact Endo International?
Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]
MarketBeat Community Rating for Endo International (NASDAQ ENDP)
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
